These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27099961)

  • 21. Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach.
    Allegaert K; Cosaert K; van den Anker JN
    Curr Pharm Des; 2015; 21(39):5674-9. PubMed ID: 26323412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining crystalline and polymeric excipients in API solid dispersions - Opportunity or risk?
    Veith H; Wiechert F; Luebbert C; Sadowski G
    Eur J Pharm Biopharm; 2021 Jan; 158():323-335. PubMed ID: 33296719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An observational study of blood concentrations and kinetics of methyl- and propyl-parabens in neonates.
    Mulla H; Yakkundi S; McElnay J; Lutsar I; Metsvaht T; Varendi H; Nellis G; Nunn A; Duncan J; Pandya H; Turner M
    Pharm Res; 2015 Mar; 32(3):1084-93. PubMed ID: 25236342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk assessment of neonatal excipient exposure: lessons from food safety and other areas.
    Turner MA; Duncan JC; Shah U; Metsvaht T; Varendi H; Nellis G; Lutsar I; Yakkundi S; McElnay JC; Pandya H; Mulla H; Vaconsin P; Storme T; Rieutord A; Nunn AJ
    Adv Drug Deliv Rev; 2014 Jun; 73():89-101. PubMed ID: 24239480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of two alternative study designs in assessment of medicines utilisation in neonates.
    Nellis G; Lutsar I; Varendi H; Toompere K; Turner MA; Duncan J; Metsvaht T
    BMC Med Res Methodol; 2014 Jul; 14():89. PubMed ID: 25027048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of Low-Molecular-Weight Excipients on the Phase Behavior of PVPVA64 Amorphous Solid Dispersions.
    Lehmkemper K; Kyeremateng SO; Degenhardt M; Sadowski G
    Pharm Res; 2018 Jan; 35(1):25. PubMed ID: 29305717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances in Co-processed APIs and Proposals for Enabling Commercialization of These Transformative Technologies.
    Schenck L; Erdemir D; Saunders Gorka L; Merritt JM; Marziano I; Ho R; Lee M; Bullard J; Boukerche M; Ferguson S; Florence AJ; Khan SA; Sun CC
    Mol Pharm; 2020 Jul; 17(7):2232-2244. PubMed ID: 32392068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemometric study of the excipients' influence on polymorphic-behavior. Mefenamic acid as case of study.
    Antonio M; Calvo NL; Maggio RM
    J Pharm Biomed Anal; 2019 Jun; 170():8-15. PubMed ID: 30901720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets.
    Kokott M; Lura A; Breitkreutz J; Wiedey R
    Eur J Pharm Biopharm; 2021 Nov; 168():122-130. PubMed ID: 34474110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prevalence and pattern of pharmaceutical and excipient exposure in a neonatal unit in Slovenia.
    Fister P; Urh S; Karner A; Krzan M; Paro-Panjan D
    J Matern Fetal Neonatal Med; 2015; 28(17):2053-61. PubMed ID: 25316561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium].
    Kołodziejczyk MK; Kołodziejska J; Zgoda MM
    Polim Med; 2012; 42(2):121-32. PubMed ID: 23016443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmaceutical excipients with potential to cause adverse effects in paediatric nasal medicines.
    Stjepanovic AN; Todorovic NB; Tesic TZ; Komazec ZS; Canji-Panic JM; Lalic-Popovic MN
    Regul Toxicol Pharmacol; 2022 Aug; 133():105225. PubMed ID: 35817211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered.
    Valeur KS; Holst H; Allegaert K
    Pharmaceut Med; 2018; 32(4):251-258. PubMed ID: 30174435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polyoxylglycerides and glycerides: effects of manufacturing parameters on API stability, excipient functionality and processing.
    Jannin V; Rodier JD; Musakhanian J
    Int J Pharm; 2014 May; 466(1-2):109-21. PubMed ID: 24607211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic excipients: Importance of clinical awareness of inactive ingredients.
    Ionova Y; Wilson L
    PLoS One; 2020; 15(6):e0235076. PubMed ID: 32584876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excipients in Anesthesia Medications.
    Burbridge MA; Jaffe RA
    Anesth Analg; 2019 May; 128(5):891-900. PubMed ID: 29505449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selecting Excipients Forming Therapeutic Deep Eutectic Systems-A Mechanistic Approach.
    Wolbert F; Brandenbusch C; Sadowski G
    Mol Pharm; 2019 Jul; 16(7):3091-3099. PubMed ID: 31095911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in pharmaceutical taste masking technologies: a patent review.
    Ayenew Z; Puri V; Kumar L; Bansal AK
    Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):26-39. PubMed ID: 19149727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ¹³C solid-state NMR analysis of the most common pharmaceutical excipients used in solid drug formulations, Part I: Chemical shifts assignment.
    Pisklak DM; Zielińska-Pisklak MA; Szeleszczuk Ł; Wawer I
    J Pharm Biomed Anal; 2016 Apr; 122():81-9. PubMed ID: 26845204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excipient variability and its impact on dosage form functionality.
    Dave VS; Saoji SD; Raut NA; Haware RV
    J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.